Key result
Simulated remote pacemaker follow-up cuts costs ~21% vs. in-person visits.
Why the study?
Patients with anti-bradycardia pacemakers have limited access to remote monitoring due to a controversial cost-benefit ratio and implementation barriers, while reimbursed patient transportation costs remain high.
Does remote follow-up reduce costs compared to in-office follow-up in patients with pacemakers using reimbursed transportation?
Cross-Sectional (n=41)
No
Does remote follow-up reduce costs compared to in-office follow-up in patients with pacemakers using reimbursed transportation?
Remote monitoring of pacemakers offers significant cost savings by reducing reimbursed transportation expenses, with high patient acceptance.
Should not yet change pacemaker follow-up practice; leaves open prospective validation of modeled remote-care savings.
Background: Digital technologies can contribute to healthcare democratization in an ethical, safe, and sustainable context. The remote monitoring of implantable cardiac devices enables the follow-up of patients from a distance. Patients with anti-bradycardia pacemakers represent the largest group and have the least access to this technology due to the controversial cost–benefit ratio and barriers to its widespread implementation, such as equipment costs and organizational challenges. In contrast, reimbursed transportation in Portugal reached approximately 82 million euros in 2024. Objectives: The aim of the present study was to assess the financial viability of remote pacemaker follow-up in a Portuguese district hospital, comparing the non-urgent transportation costs and the investment in remote monitoring equipment while measuring user acceptance and satisfaction. Methods: A total of 41 surveys were conducted with patients who received a pacemaker and used publicly reimbursed transportation. The projected costs were calculated for two simulated protocols: the first involved in-person visits every six months, while the second involved in-person visits every two years with remote consultations every six months, over the expected lifespan of the devices. EZR, version 1.61, was used. Results: Our data showed a 74% overall reduction in face-to-face visits. The implementation of remote follow-up would result in a cost saving of EUR 373/patient (21.2%), with total reimbursement (p = 0.01151). The savings increased to 33.3%, reaching EUR 764/patient (p = 0.0002742) for distances greater than 60 km (round trip) for ambulance users with total reimbursement. Acceptance and satisfaction achieved 88%. Conclusions: Remote monitoring of pacemakers can be a financially viable alternative with high acceptance and satisfaction.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a cross-sectional in Pacemakers (n=41). Remote pacemaker follow-up vs. In-person visits every six months was evaluated on Financial viability (cost savings) (p=0.01151). Simulated remote pacemaker follow-up saved EUR 373 per patient (21.2%, p=0.01151) compared to in-person visits, with 88% patient acceptance and satisfaction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: